Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Delaware: below-average open trial sites
218 of 652 in-state trials are recruiting (33%); below the 37% national average by 4 percentage points.
According to ClinicalTrials.gov-derived indexes, Delaware sits in the lower half of US states by in-state trial count (#38 of 52 states by registered in-state trial count).
Delaware: 652 US clinical trials with in-state sites, 218 recruiting.
Delaware has 652 registered US clinical trials with a study site in-state, 218 of them currently recruiting (below the 37% national average by 4 percentage points). 174 of these trials are in Phase 3 (late-stage) and 162 in Phase 2. The most frequently studied condition in Delaware is Breast Cancer, with 17 linked trials.
Thin-volume Delaware archive
Delaware's in-state trials target 18,291 patients on average (p96 by trial size among 52 states with enrollment data), larger, multi-site studies than most states. Treat this page as a compact local index (thin-volume · mid-open), then jump to recruiting trials or methodology rather than expecting hub-scale coverage.
Below-average open enrollment
Delaware still shows 218 recruiting of 652 in-state trials (33% open), but below the 37% national average by 4 percentage points, so archived statuses weigh heavier than the national baseline.
- 33%
- open (below national share)
- 218
- still recruiting despite cool share
- 162
- Phase 2 rows in this footprint
- 17
- top: Breast Cancer
Recruiting share is below the 37% national average by 4 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Delaware vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
652 Top 73% more indexed trials than 27% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Delaware on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Delaware open-enrollment share sits below the national baseline.
218 of 652 in-state trials (33.4%) are recruiting, against 37% nationally (-3.6 percentage points). Counts include every study with at least one recorded site in the state.
-
Newark dominates Delaware's trial geography.
Newark lists 372 of 652 in-state trials (57.1%) across 107 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in Delaware.
17 of 652 in-state trials (2.6%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
Delaware sponsorship is fragmented across many organizations.
National Cancer Institute (NCI) appears on 43 of 652 in-state trials (6.6%). Sponsor identity is as filed on ClinicalTrials.gov.
-
299 Delaware trials carry a completed status.
299 of 652 (45.9%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 299 |
| Recruiting | 218 |
| Active | 135 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 3 | 174 |
| Phase 2 | 162 |
| NA | 136 |
| Phase 1 | 36 |
| Phase 4 | 27 |
Top Conditions
Top Sponsors
Where trials run in Delaware
Newark carries 372 of Delaware's 652 indexed trials (57%) across 107 named sites, ahead of Wilmington at 265. 7 cities clear five listed trials, together naming 231 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Newark | 372 | 107 |
| Wilmington | 265 | 99 |
| Lewes | 50 | 8 |
| Rehoboth Beach | 20 | 1 |
| Millville | 16 | 1 |
| Dover | 14 | 11 |
| Milford | 6 | 4 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Trial size large
Delaware's in-state trials target 18,291 patients on average (p96 by trial size among 52 states with enrollment data), larger, multi-site studies than most states.
Delaware: in-state trial volume sits in the thin tercile
Sites spread across 7 cities with five or more listed trials, led by Newark (372, 57% of the state total) and Wilmington (265), together naming 231 distinct research locations.
Phase mix: 174 Phase 3 vs 162 Phase 2 (balanced across stages).
Top condition: Breast Cancer (17 trials); top sponsor National Cancer Institute (NCI) (43).
thin-volume · mid-open figures (652 trials · 33% open) describe registry geography under the trial size large read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Delaware on in-state trial volume
Cross-state peers under the trial size large read (thin-volume · mid-open), not the same-state browse list.
Similar thin-volume peers (± open share)
- Idaho · 633 trials · 26% recruiting
- New Mexico · 579 trials · 29% recruiting
- Rhode Island · 753 trials · 34% recruiting
- Mississippi · 500 trials · 27% recruiting
- Alaska · 485 trials · 25% recruiting
Similar mid-open peers (± trial volume)
- Illinois · 33% recruiting · 6,854 trials
- Tennessee · 33% recruiting · 3,520 trials
- New Jersey · 34% recruiting · 3,402 trials
- Maryland · 34% recruiting · 6,441 trials
- Florida · 33% recruiting · 10,986 trials